Amneal (AMRX) Director J. Kevin Buchi Exercises Options, Sells Shares

What Happened

• J. Kevin Buchi, a director of Amneal Pharmaceuticals (AMRX), exercised derivative securities and disposed of the resulting 168,573 shares on August 11, 2026. The weighted-average sale price was $17.18 per share, for total proceeds of approximately $2,896,084. The filings show the shares were sold (i.e., the shares were not retained).

Key Details

• Transaction date: 2026-08-11; Form 4 filed: 2026-08-13 (appears timely).
• Transaction type/code: M (exercise or conversion of derivative); disposition = sale of shares.
• Shares sold: 168,573; weighted-average price reported: $17.18; total proceeds ≈ $2,896,084.
• Footnote: The $17.18 is a weighted average. Sales occurred in multiple transactions at prices ranging from $17.07 to $17.31 per share. The reporting person offered to provide a price-by-price breakdown on request.
• Shares owned after the transaction: not specified in the provided filing extract.

Context

• For retail investors: this was an exercise of derivative awards (likely options) followed by an immediate sale of the shares — a routine liquidity event for insiders, not necessarily an indicator of company outlook. The filing appears to have been made within the standard reporting window.